Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPQBN0)

Drug Name

Heptyl-Beta-D-Glucopyranoside Drug Info

Synonyms

78617-12-6; HEPTYL-BETA-D-GLUCOPYRANOSIDE; Heptyl beta-D-glucopyranoside; (2R,3R,4S,5S,6R)-2-(Heptyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Heptyl-b-D-glucopyranoside; Heptyl b-D-glucopyranoside; B7G; n-Heptyl-I(2)-D-glucopyranoside; AC1L9LOI; heptyl-; n-Heptyl-ss-D-glucopyranosid; SCHEMBL333088; MolPort-003-935-703; C13H26O6; ZINC48016017; MFCD00063299; GC5331; AKOS027251086; DB03338; API0002901; AK187162; W0562; FT-0626931; n-Heptyl beta-D-glucopyranoside, ~98% (GC); A-7798; n-Heptyl beta-D-gluc

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 448173
CAS Number: CAS 78617-12-6
TTD Drug ID: DMPQBN0

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Peroxisome proliferator-activated receptor delta (PPARD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GFT-505	DM7ZOAE	Non-alcoholic steatohepatitis	DB92.1	Phase 3	[2]
MBX-8025	DMNTCV4	Obesity	5B81	Phase 2/3	[3]
T3D-959	DMR3245	Alzheimer disease	8A20	Phase 2	[4]
T3D-959	DMR3245	Alzheimer disease	8A20	Phase 2	[5]
KD3010	DMNFDYE	Metabolic disorder	5C50-5D2Z	Phase 1	[6]
SAR351034	DM15PG9	Dyslipidemia	5C80-5C81	Phase 1	[7]
CER-002	DMLBKZV	Dyslipidemia	5C80-5C81	Phase 1	[8]
PMID25416646-Compound-Figure5-C	DM17FKL	N. A.	N. A.	Patented	[9]
GW-501516	DMPL2KM	Type-1 diabetes	5A10	Discontinued in Phase 4	[10]
Sodelglitazar	DMJ816F	Hyperlipidaemia	5C80	Discontinued in Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting FK506-binding protein 1A (FKBP1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GPI-1485	DM64ZYM	Parkinson disease	8A00.0	Phase 2	[12]
SDZ-281-240	DMPZ67G	Pruritus	EC90	Phase 2	[13]
AP1903	DM2LU8M	Transplant rejection	NE84	Phase 1/2	[14]
Gpi-1046	DMD5WK4	Parkinson disease	8A00.0	Terminated	[15]
MYRISTIC ACID	DMYX0BL	Discovery agent	N.A.	Investigative	[15]
4-Hydroxy-2-Butanone	DM7BQ65	Discovery agent	N.A.	Investigative	[16]
L-709,587	DM9KCYQ	Discovery agent	N.A.	Investigative	[16]
Methyl Methylsulfinylmethyl Sulfide	DMOCXLW	Discovery agent	N.A.	Investigative	[16]
Rapamycin Immunosuppressant Drug	DM678IB	Discovery agent	N.A.	Investigative	[16]
FKB-001	DM9K834	Discovery agent	N.A.	Investigative	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
FK506-binding protein 1A (FKBP1A)	TTMW94E	FKB1A_HUMAN	Inhibitor	[1]
Peroxisome proliferator-activated receptor delta (PPARD)	TT2JWF6	PPARD_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
2	Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
3	ClinicalTrials.gov (NCT00701883) Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol. U. S. National Institute of Health. 2008.
4	Phrma report (2013 Alzheimers disease)
5	T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2016;51(1):123-38.
6	Kalypsys nearing completion of phase Ia study of KD3010 for metabolic disorders. Kalypsys. 2007.
7	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
8	Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010 May; 30(5): 894-899.
9	PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
10	Lipid effects of peroxisome proliferator-activated receptor- agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.Arterioscler Thromb Vasc Biol.2012 Sep;32(9):2289-94.
11	Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.
12	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
13	Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol. 1996 Apr;106(4):701-10.
14	Using gene transfer to circumvent off-target effects. Gene Ther. 2008 May;15(10):759-64.
15	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
16	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.